Theratechnologies, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA88338H7040
CAD
4.47
2.43 (119.12%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

35.47 k

Shareholding (Feb 2025)

FII

32.25%

Held by 65 FIIs

DII

67.75%

Held by 2 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Operating profit has grown by an annual rate 19.11% of over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2

Risky -

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 206 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.18

stock-summary
Return on Equity

7.00%

stock-summary
Price to Book

-5.35

Revenue and Profits:
Net Sales:
25 Million
(Quarterly Results - May 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
90.21%
0%
90.21%
6 Months
68.05%
0%
68.05%
1 Year
13.74%
0%
13.74%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Theratechnologies, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
6.03%
EBIT Growth (5y)
19.11%
EBIT to Interest (avg)
-2.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.18
Sales to Capital Employed (avg)
3.30
Tax Ratio
5.08%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.26%
ROCE (avg)
26.97%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-5.35
EV to EBIT
33.67
EV to EBITDA
24.67
EV to Capital Employed
36.32
EV to Sales
2.13
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
107.87%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Feb 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 65 Foreign Institutions (32.25%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - May'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended May 2025 is -17.00% vs 26.05% in May 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended May 2025 is -584.62% vs 109.56% in May 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "May'25",
        "May'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "24.90",
          "val2": "30.00",
          "chgp": "-17.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.10",
          "val2": "7.60",
          "chgp": "-127.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.60",
          "val2": "3.70",
          "chgp": "-56.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.50",
          "val2": "-1.20",
          "chgp": "-25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.30",
          "val2": "1.30",
          "chgp": "-584.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-112.80%",
          "val2": "197.10%",
          "chgp": "-30.99%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Nov'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Nov 2024 is 5.97% vs 6.56% in Nov 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Nov 2024 is 65.12% vs 47.06% in Nov 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Nov'24",
        "Nov'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "117.10",
          "val2": "110.50",
          "chgp": "5.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "15.10",
          "val2": "-8.00",
          "chgp": "288.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "14.30",
          "val2": "14.10",
          "chgp": "1.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.80",
          "val2": "-6.90",
          "chgp": "-42.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.30",
          "val2": "-32.40",
          "chgp": "65.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "96.40%",
          "val2": "-112.60%",
          "chgp": "20.90%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - May'25 - YoYstock-summary
May'25
May'24
Change(%)
Net Sales
24.90
30.00
-17.00%
Operating Profit (PBDIT) excl Other Income
-2.10
7.60
-127.63%
Interest
1.60
3.70
-56.76%
Exceptional Items
-1.50
-1.20
-25.00%
Consolidate Net Profit
-6.30
1.30
-584.62%
Operating Profit Margin (Excl OI)
-112.80%
197.10%
-30.99%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended May 2025 is -17.00% vs 26.05% in May 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended May 2025 is -584.62% vs 109.56% in May 2024

Annual Results Snapshot (Consolidated) - Nov'24stock-summary
Nov'24
Nov'23
Change(%)
Net Sales
117.10
110.50
5.97%
Operating Profit (PBDIT) excl Other Income
15.10
-8.00
288.75%
Interest
14.30
14.10
1.42%
Exceptional Items
-9.80
-6.90
-42.03%
Consolidate Net Profit
-11.30
-32.40
65.12%
Operating Profit Margin (Excl OI)
96.40%
-112.60%
20.90%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Nov 2024 is 5.97% vs 6.56% in Nov 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Nov 2024 is 65.12% vs 47.06% in Nov 2023

stock-summaryCompany CV
About Theratechnologies, Inc. stock-summary
stock-summary
Theratechnologies, Inc.
Pharmaceuticals & Biotechnology
Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition.
Company Coordinates stock-summary
Company Details
2015 Peel St 5th Floor , MONTREAL QC : H3A 1T8
stock-summary
Tel: 1 514 33678001 514 3367800
stock-summary
Registrar Details